How Human Embryonic Stem Cells Sparked a Revolution

The human embryonic stem cells are obtained from the undifferentiated inner mass cell of the human embryo and human fetal tissue. The human embryonic stem cell can replicate indefinitely and produce non-regenerative tissue such as myocardial and neural cells.
This potential of human embryonic stem cell allows them to provide an unlimited amount of tissue for transplantation therapies to treat a wide range of degenerative diseases. Hence, human embryonic stem cells are used in the treatment of various diseases such as Alzheimer's disease, cancer, blood and genetic disorders related to the immune system and others.
Download PDF Brochure @ Click Here !!!
Top Dominating Key Players :
  1. BD
  2. Takara Bio Inc.
  3. Geron
  4. Thermo Fisher Scientific Inc.
  5. ViaCyte, Inc.
  6. R&D Systems, Inc.
  7. QIAGEN
  8. CellGenix GmbH
  9. Vitrolife
  10. Lonza

The global human embryonic stem cell market is expected to grow in upcoming years, factors driving the growth of market are rise in incidences of neurological disorders, increase in investment by government and other organization for research activities, awareness among people about stem cell therapeutic potency for disease treatment.
On the other hand emerging stem cell banking services is expected to offer lucrative opportunities in growth of human embryonic stem cell market.
The global human embryonic stem cell market is segmented on the basis of product type, application and end user. Based on product type, the market is segmented as totipotent stem cell, pluripotent stem cell and unipotent stem cell. On the basis of application, the global human embryonic stem cell market is segmented into regenerative medicine, stem cell biology research, tissue engineering and toxicology testing. Based on end users, the market is segmented as therapeutics companies, cell & tissue banks, tools & reagents companies and others.
Source : The Insight Partners

Comments

Post a Comment

Popular posts from this blog

Cell Line Development Market Rising Demand for Digitization in Organizations and Growth till 2027

Image
The growth of the is driven by the factors such as increase in the demand for innovative products from biopharmaceutical and biotechnology companies, the presence of key market players, and extensive R&D conducted by various academic and research institutes in the North America region. The medical biotechnology has undergone revolutions as a result of various development programs, business strategies that helps to produce, discover, or alter various biomolecules and organisms through bioengineering approaches. The Biotech Startup Revolution has also assisted in promoting the new ventures holding promising and innovative ideas in the country and supported in maximizing the revenue generation and thus the economic position of North America in the global cell line development market. Register for a free Trial today and gain instant*access @ Click Here Top Dominating Key Players: Merck KGaA Thermo Fisher Scientific, Inc. Sartorius AG SELEXIS BioFactura, Inc. WuXi AppT
Read more

Better Opportunities for Oncology Biosimilars

Image
Biosimilars are the fastest-growing class of therapeutic products across the globe. Biosimilars are biologics that serves as interchangeable products offering additional treatment options to a branded drug counterpart, potentially reducing the cost of the prescribed biologics. The biosimilar therapies have been for chronic disease management and supportive care since a few years, however the use of these biosimilars are expected to be applied soon for treatment of various types of cancers referred to as oncology biosimilars. Get PDF Sample Copy of this Report !!! The market for oncology biosimilars market is expected to witness growth due to extensive research undertaken by market players to bring biosimilars for cancer treatment in the market as well as rapid approval by regulatory authorities for commercialization of these products. However, high costs involved in the research and complexity involved in the formulation of these biologics are likely to hinder market growth.
Read more